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ABSTRACT We have solved the structure of a chorismate
mutase (chorismate pyruvatemutase, EC 5.4.99.5), the 1.9-
crstal structure of the monofunctional enzyme from BaciUls
sublis. The structure determination process was an unusual
one, involving 12 monomers of the enzyme in the asymmetric
unit. This structure was solved by the multiple isomorphous
replacement method with partal structure phase combination
and mo lar averaging. The final model, which includes 1380
residues and 522 water molecules in an asymmetric unit, has
been refind at 1.9 A and the current crystallographic R value
b 0.201. The B. subtiUs chorismate mutase is a homotrimer,
with -sheets from each monomer packdng to form the core of
a pseudo-a1-barrel with helices on the outside ofthe trimer. In
addition, the active sites have been located by using data from
a complex with an endo-oxabicydic inhibitor that mimics the
transition state of the reaction. The structure of this complex
has been reined to 2.2 A with a current R value of 0.182 for
amodel that clude 1388 residues, 12 inhibitor moleculs, and
530 water molecules in the asymmetric unit. In each trimer,
three equivalent active sites are located at the interfaces of two
adjacent subunits.
Chorismate mutase (chorismate pyruvatemutase, EC
5.4.99.5) lies at a branch point in the biosynthetic pathway of
aromatic amino acids (1). It is the only characterized enzyme
that catalyzes a pericyclic process, the unimolecular rear-
rangement of chorismate to prephenate (see Fig. 1). Neither
the mechanistic details of the enzyme-catalyzed rearrange-
ment nor the origins of the 2 x 106-fold rate enhancement
over the uncatalyzed process (2) are known. The enzymatic
and nonenzymatic rearrangement of chorismate to prephe-
nate is a concerted, asynchronous reaction, which proceeds
via a transition state with chair-like geometry (3, 5). Strong
binding of an endo-oxabicycic transition state analog (4)
(Fig. 1) suggests that the enzyme-catalyzed rearrangement
also likely proceeds via the chair-like transition state (3, 5)
without observed intermediates. However, neither the rate-
limiting transition state nor the mechanistic pathway of this
reaction has been determined.
Catalytic antibodies with chorismate mutase activities
have also been prepared, accelerating the reaction by a factor
of 2 x 104 in one case (6) and by a factor of2 x 102 in another
(7, 8). Comparison of the unimolecular rearrangement of
chorismate to prephenate in the different proteins should
provide insights into the evolution of specificity, catalytic
mechanism, and origins ofrate enhancement in both enzymes
and engineered proteins. Furthermore, as chorismate mutase
lies at a branch point in the shikimate pathway, which exists
only in bacteria, fungi, and higher plants, the enzyme may be
extremely useful in development of herbicides and antibac-
terial therapeutics. The poor sequence homology between
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FIG. 1. Claisen rearrangement of chorismate to prephenate,
proceeding via a transition state with chair-like geometry (3, 5). The
endo-oxabicyclic inhibitor closely mimics the putative transition
state (4).
chorismate mutases from different organisms also provides
potential for design of specific inhibitors targeted at specific
plants and microorganisms.
We report here the structure of a chorismate mutase, the
1.9-A crystal structure of the monofunctional enzyme from
the Marburg strain of Bacillus subtilis. This is the smallest
natural chorismate mutase known, with 127 residues per
subunit (9, 10). Furthermore, this enzyme is particularly
amenable to study since, unlike other chorismate mutases
(11, 12), it is monofunctional, nonallosteric, unaffected by
end-product amino acids and effectors, and follows Michael-
is-Menten kinetics (10). We have also located the active sites
by using data at 2.2 A from a complex of the enzyme with an
endo-oxabicycic inhibitor that mimics the putative transition
state of the reaction. Although the structures of the enzyme
and its active site are reported here,j a detailed analysis ofits
mechanism of catalysis and results of refinement of both the
native enzyme and the transition state analog complex at high
resolution will be published elsewhere.
MATERIALS AND METHODS
Purification and Crystallization. Purified chorismate mu-
tase from B. subtilis (10) was a gift from Jeremy R. Knowles
(Harvard University). The B. subtilis chorismate mutase
native crystals were grown with protein solution (12 mg/ml)
in microdialysis wells dialyzed against solution containing 5
mM Tris HCl, 1 mM 2-mercaptoethanol, 0.5 mM NaN3, 0.1
Abbreviation: MIR, multiple isomorphous replacement.
*The atomic coordinates and structure factors have been deposited
in the Protein Data Bank, Chemistry Department, Brookhaven
National Laboratory, Upton, NY 11973 (references 1CHS, 1CHT).
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Table 1. Heavy atom derivative preparation
Concentration, Time,
Compound mM pH days
Ethyl mercury phosphate 0.2 5.3 2
Iridium hexachloride 0.2 5.3 2
Osmium hexachloride 0.2 5.3 2
Osmium hexachloride 1.0 5.3 2
mM EDTA, and 11-12% polyethylene glycol (PEG) 3350 at
pH 5.3. Crystals grew in -7 days to dimensions of 0.4 x 0.5
x 0.6 mm3 and diffracted to 1.9-A resolution. These crystals
belong to space group P21 (a = 102.4 A, b = 68.3 A, c = 102.8
A, A = 105.60) and have the unusual number of 12 monomers
of the enzyme in its asymmetric unit.
Stucture Determination. Heavy atom derivatives were
prepared by soaking crystals in a stabilizing solution (20 mM
Bicine/40%o PEG 3350/0.1 mM NaN3, pH 5.3) containing
heavy atom reagents (see Table 1 for details of the soaking
conditions). All data sets were collected at the Resource for
Crystallography located in the laboratory of N. h. Xuong
(University of California, San Diego) with the use of Mark
III, two multiwire proportional chambers (13), and graphite-
monochromated CuKa radiation from a Rigaku RU200 ro-
tating anode (see Table 2 for data collection statistics).
Difference Patterson maps were used to locate the heavy
atom sites. Twelve mercury sites were located by manual
interpretation of the difference Patterson map of the ethyl
mercury phosphate derivative and single isomorphous re-
placement phases calculated with these sites were used in
difference and crossed-phase Fourier maps to locate the
remainder of heavy atom binding sites in the mercury deriv-
ative and in the other derivatives. Heavy atom parameters
were then refined with programs HEAVY (14) and PHASES.§
Anomalous scattering was used to determine the set ofheavy
atom sites with the correct handedness.
The multiple isomorphous replacement (MIR) phase de-
termination was particularly challenging due to the large
numbers ofheavy atom sites in various derivatives (Table 2).
Low-concentration heavy atom solutions were required to
minimize nonisomorphism, resulting in low occupancy heavy
atom sites, weak MIR phases, and uninterpretable electron
density maps. However, this problem was solved by biosyn-
thetic preparation ofa selenomethionine substituted enzyme.
The selenomethionine enzyme was prepared by growing
Escherichia coli strain BL21 transformed with pBSCM2
(plasmid containing the chorismate mutase gene) in minimal
medium supplemented with 19 amino acids and selenome-
Furey, W. & Swaminathan, S., American Crystallographic Asso-
ciation Meeting, April 8-13, 1990, New Orleans.
thionine. Data from this selenomethionine protein were also
collected at the Resource for Crystallography located in the
laboratory of N. h. Xuong. MIR phases from refinement of
the heavy atom sites of the soaked derivatives were used in
crossed-phase Fourier maps to obtain the selenium sites.
Seventy-two selenium sites were found and they correspond
to six highly occupied selenium sites in each monomer.
Incorporation of this selenomethionine derivative into MIR
phase refinement finally produced an interpretable electron
density map (see Table 2 for summary of multiple isomor-
phous replacement data).
The electron density map calculated with these MIR
phases allowed a partial model polyalanine trace of all the
helices and (-strands to be made using FRODO (15, 16). Phase
combination of the MIR phases and the partial polyalanine
model phases (17) further improved the electron density and
allowed identification of side chains and loop regions to
complete the trace. Then, 144-fold improper noncrystallo-
graphic symmetry averaging was done, using hand drawn
masks for each monomer, electron density calculated from
MIR phases, and Bricogne's averaging programs (18) to
provide an independent crystallographic check of the model.
The final model consisting of 1380 residues and 522 water
molecules in the asymmetric unit was refined by using
XPLOR (19) to an R value of 0.194 for 71,847 reflections from
10.0-1.9 A. The root mean square deviations from ideal
values are 0.014 A for bond lengths and 2.92° for bond angles.
To identify and study the active site of chorismate mutase,
we also determined the three-dimensional structure of its
complex with an endo-oxabicyclic transition state analog (4).
This inhibitor was a gift from Paul A. Bartlett (University of
California, Berkeley). Crystals ofthe enzyme-inhibitor com-
plex were prepared by soaking native crystals in a stabilizing
solution (5 mM Tris HCl/40%o PEG 3350 pH 5.3) containing
0.5 mM inhibitor for 8 days. Data to 2.2 A with Rsym = 11.0%o
were collected on the Hamlin Multiwire Systems Mark II (13)
at Rutgers University. Fo - F, difference Fourier density (F.
is observed structure factor of the complex of chorismate
mutase with the endo-oxabicyclic inhibitor; F, and phases are
from the refined model of the unbound enzyme) clearly
revealed the inhibitor binding in the active site of the enzyme
(see Fig. 3). The refined model ofthe native enzyme was used
as the starting model for refinement of this complex. All 12
inhibitors in the asymmetric unit were subsequently incor-
porated into the model by using F. - F, and 2Fo - F, maps
(Fo is observed structure factor of the complex and F, is
structure factor of the refined model of the complex without
its inhibitors). This model, with 1388 residues, 12 inhibitor
molecules, and 530 water molecules, has been refined to 2.2
A with R value currently at 0.182.
Table 2. Crystallographic and MIR data
Parameter Native HG IR OS1 OS2 Se-Met
Resolution, A 1.9 2.7 2.5 2.5 2.5 2.2
Reflections, observed 208,894 168,648 213,528 233,898 216,981 182,472
Reflections, unique 80,528 26,102 41,120 36,665 37,547 46,010
Completeness, % 75.0 71.0 86.9 76.8 77.8 75.8
R,sym % 5.5 5.6 6.3 4.7 6.8 5.3
MIR statistics
Number of sites 24 24 24 24 72
Riso, % 9.7 15.2 12.2 21.0 15.5
Rc,uns (15.0-3.0 A) 0.67 0.98 0.98 1.00 0.60
Phasing power (15.0-3.0 A) 0.77 1.05 1.15 1.23 1.11
Rsym is the R factor on F between symmetry-related reflections; MIR statistics were calculated by using HEAVY (14); Ris
= £ (lFderI - IFatl)/Y IFnalt; Rullis = X [IFHI - (IFPHI - lFpl)]/Z IFHI; phasing power = (FH)/(closure error); figure of merit
(15.0-3.0 A) = 0.66. HG, ethyl mercury phosphate; IR, iridium hexachloride; OS1 and OS2, osmium hexachloride; Se-Met,
selenomethionine.
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RESULTS AND DISCUSSION
Monomer Structure. The chorismate mutase monomer
consists of a single domain (Fig. 2a). Its N-terminal methi-
onine and the 12 C-terminal residues are not observed in the
electron density map because of structural disorder. The
remainder of the monomer folds into a five-stranded mixed
(3-sheet packed against an 18-residue a-helix and a two-turn
3io helix. The C-terminal tail consists of one turn of 3io helix
(residues 112-115) that protrudes away from the ,B-sheet on
the face opposite the helices into the solvent region.
The three inner strands, I, II, and IV, of the (3-sheet
(composed of residues 2-11, 44-50, and 88-94) are antipar-
allel and the two outer strands, III and V (composed of
residues 73-76 and 107-109), are parallel. This (3-sheet is
characterized by +2x,+lx,-2,-2 topology (21). The 18-
residue a-helix Hi (residues 18-34) is connected to strands I





FIG. 2. (a) Ribbon drawing of chorismate mutase monomer
generated by using MOLsCRIPr (20). fl-Strands (I-V) and helices (Hi
and H2) are numbered in order from the N terminus. N and C termini
are labeled N and C, respectively. (b) Ribbon drawing (20) of
chorismate mutase trimer in a view looking down the barrel/pseudo-
threefold axis.
310 helix H2 is parallel to the a-helix and is connected to
strands II and III by 9- and 8-residue loops, respectively (see
Fig. 2a).
Trimer Structure. Prior to structure determination by x-ray
crystallography, the monofunctional chorismate mutase from
B. subtilis was reported to be a homodimer in one study (10)
and a homotrimer in another (22). Interpretation of the
electron density map clearly revealed the enzyme to be a
homotrimer with the three monomers packing to form a
pseudo-a(-barrel. The subunits of the trimer are related by
pseudo-3-fold symmetry (Fig. 2b). The core of this trimer
consists of large portions of the (3-sheet (strands I-IV) from
each monomer, together forming a closed barrel of (-strands.
Side chains protruding into the core of the barrel are almost
entirely hydrophobic (lle-3, Val-43, Leu-46, Pro-72, Met-76,
and Met-92). This core of (3-sheets is surrounded by three
a-helices and three 310 helices.
Near the surface of the trimer, the interfaces between
adjacent subunits form three equivalent clefts (Fig. 3a). The
walls of each cleft are composed of the 310 helix (residues 59,
60, 62, and 63), a loop (residues 66-71), and (3-strand III
(residues 72-76) from one subunit, and of (3-strand V (resi-
dues 104-108), parts of (-strands I and IV (residues 7-10 and
89-91), and the C-terminal tail (residues 111-115) from the
adjacent subunit. This cleft is capped with a loop (residues
78-89) from the adjacent subunit.
Active Site Structure. The active site of chorismate mutase
has been located by using data from a complex ofthe enzyme
with an endo-oxabicyclic transition state analog (4), Ki = 3
,uM (10). Binding of this inhibitor in the cleft described above,
creating a shared active site, is clearly indicated in the
difference electron density (Fig. 3a). Refinement of this
model to 2.2 A indicates little change in the conformation of
the enzyme upon ligation in the active-site region.
Numerous interactions are present between enzyme and
inhibitor (for details, see legend to Fig. 3b). These interac-
tions include hydrophobic contacts (between the inhibitor
and side chains Phe-57 and Ala-59 from one monomer and
Leu-115 from the adjacent monomer), ionic contacts (be-
tween a carboxylate group on the inhibitor and Arg-7 and
Arg-90 and between the other carboxylate group and Arg-
116), and polar contacts (between the hydroxyl of the inhib-
itor and side chains of Glu-78, Cys-75, and main chain amide
of Cys-75 and between the ether oxygen of the inhibitor and
side chain of Arg-90). However, there are no functional
groups capable of proton transfer to the ether oxygen of the
inhibitor. This observation is consistent with the flat pH
profile of kct/Km between pH 4 and pH 9 and the lack of
solvent isotope effect for the B. subtilis chorismate mutase
(23), strongly suggesting that the enzymatic rearrangement of
chorismate to prephenate is a pericyclic process similar to the
uncatalyzed reaction. In this case, the chemistry of the
rearrangement is an inherent property of chorismate itself
and chorismate mutase serves as a template for accelerating
the reaction and may serve to stabilize the transition state by
specific interactions-e.g., of the ether oxygen with Arg-90
or the carboxylate anions with the groups mentioned above.
Detailed analysis of the active site structure of this transition
state analog complex and the complexes of chorismate mu-
tase with prephenate and with a substrate analog will provide
more information on the origins of enzymatic rate accelera-
tion. Furthermore, the active site structure will allow for
rational design of better binding inhibitors.
Note Added In Proof. We have also solved the structure of the
complex between chorismate mutase and the product, prephenate,
which binds in 8 of the 12 active sites of the asymmetric unit. The
carboxylate groups of prephenate are in the same positions as those
of the transition state analog, and the carbonyl group of prephenate
is bound to Arg-90.
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FIG. 3. (a) Stereoview displaying the location of the active site in the trimer. The endo-oxabicyclic inhibitor binds in the cleft at the interface
of adjacent subunits. Difference Fourier density map (Fo - F, map: F. is structure factor of the complex of chorismate mutase with the
endo-oxabicycic inhibitor; F, and phases are from the refined model of the unbound enzyme) contoured at 3ais shown with Ca trace of the refined
native enzyme. (b) Stereoview showing details of the active site. The endo-oxabicyclic inhibitor is shown with active site residues. Residues B57
and B75 are from one monomer; residues C7, C78, C90, C108, and C115 are from the adjacent monomer. Interactions between the inhibitor
and the enzyme are as follows (see Fig. 1 for numbering ofatoms on the inhibitor): C3inh and C5inh, side chain of Phe-57 (3.5-3.8 A); C8ij,h, Ala-59
(3.5 A); 04.h, amide N of Lys-60 (3.4 A); C'i,h, Ca of Thr-74 (3.5 A); Olinh, amide N of Cys-75 (3.1 A); Olih, side chain of Cys-75 (3.3 A);
Olinh, side chain of Glu-78 (2.9 A); 02inh, side chain of Arg-7 (2.8 A); 02inh, side chain of Arg-90 (3.1 A); O'inh, side chain of Arg-90 (3.1 A);
03inh, side chain of Tyr-108 (3.0 A); C7inh and C9ih, side chain of Leu-115 (3.7-3.8 A); 04ih, side chain of Arg-116 (3.1-4.1 A).
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